Patents by Inventor Patrick M. Lippiello

Patrick M. Lippiello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130237550
    Abstract: The present invention relates to method of treating constipation and enhancing colonic motility by administration of 5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 4, 2011
    Publication date: September 12, 2013
    Applicant: TARGACEPT, INC.
    Inventors: Steven M. Toler, David Hosford, Patrick M. Lippiello, Geoffrey Charles Dunbar, William Scott Caldwell, Parviz Hamedani, Merouane Bencherif
  • Publication number: 20110098312
    Abstract: Method and compositions for delaying the onset or progression of retinopathy, including administering at least one neuronal nicotinic ligand are disclosed.
    Type: Application
    Filed: May 11, 2009
    Publication date: April 28, 2011
    Applicant: Targacept ,Inc
    Inventors: Merouane Bencherif, Scott N. Cullison, Patrick M. Lippiello, Steven M. Toler
  • Publication number: 20100121061
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Application
    Filed: December 8, 2009
    Publication date: May 13, 2010
    Applicant: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 7045538
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 6979695
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: December 27, 2005
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Publication number: 20030125345
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Application
    Filed: October 2, 2002
    Publication date: July 3, 2003
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 5604231
    Abstract: Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: February 18, 1997
    Inventors: Carr J. Smith, Patrick M. Lippiello, Merouane Bencherif, William S. Caldwell, Gary M. Dull
  • Patent number: 5583140
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo[2.2.1]hept-5-ene and 2-azabicyclo[2.2.2]oct-5-ene compounds.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 10, 1996
    Inventors: Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello
  • Patent number: 5559124
    Abstract: Compounds such as 2-acetoxymethylquinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 24, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5510355
    Abstract: Compounds such as 5-chloronicotine, 5-fluoronornicotine, anabaseine, 5-fluoroanabaseine, 2-acetoxymethylquinuclidine or!2-(3-pyridyl)-quinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: April 23, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5276043
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of certain anabasine compounds, certain unsaturated anabasine compounds or unsaturated nicotine compounds. Exemplary compounds are myosmine and anatabine.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: January 4, 1994
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5248690
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a phenylpyrrolidine compound.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: September 28, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwel, Patrick M. Lippiello
  • Patent number: 5242935
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a nicotine compound. Exemplary nicotine compounds are 5-fluoronicotine, 5-bromonicotine, 4.sup.1 -methylnicotine and 5-methylnicotine.
    Type: Grant
    Filed: March 6, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5242934
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a gamma-nicotine compound.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5242916
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a cytisine compound.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5232932
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pseudooxynicotine compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello
  • Patent number: 5232933
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an alpha-nicotine type compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5227385
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a ferruginine compound or a anhydroecgonine compound.
    Type: Grant
    Filed: March 13, 1992
    Date of Patent: July 13, 1993
    Assignees: Wake Forest University, R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Huw M. L. Davies, Patrick M. Lippiello
  • Patent number: 5227391
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an (R)-(+)-nicotine compound.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: July 13, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello
  • Patent number: 5214060
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pyridylalkylpiperidine compound or a pyridylalkylpyrrolidine compound.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: May 25, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello